LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Accueil・Liste d'Actions・BioNTech SE ADR

BioNTech SE ADR

Fermé

SecteurSoins de santé

102.15 -0.52

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

101.73

Max

103.94

Chiffres clés
By Trading Economics
Revenu	43M -403M
Ventes	78M 261M
Marge bénéficiaire	-154.41
Employés	6,772
EBITDA	20M -348M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+23.99% upside

Dividendes
By Dow Jones
Prochains Résultats	3 nov. 2025

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-2.4B 24B
Ouverture précédente	102.67
Clôture précédente	102.15

Sentiment de l'Actualité

By Acuity

50%

173 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

92.4 / 103.5 Support & Résistance

BioNTech SE ADR Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 juin 2025, 11:48 UTC

Principaux Mouvements du Marché

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

4 févr. 2025, 18:52 UTC

Principaux Mouvements du Marché

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15 nov. 2024, 10:28 UTC

Principaux Mouvements du Marché

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

4 août 2025, 14:14 UTC

Résultats

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped. -- Barrons.com

4 août 2025, 11:59 UTC

Résultats

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

12 juin 2025, 14:20 UTC

Acquisitions, Fusions, Rachats

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 juin 2025, 13:34 UTC

Actions en Tendance

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

10 juin 2025, 12:18 UTC

Résultats

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

20 mai 2025, 14:46 UTC

Acquisitions, Fusions, Rachats

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

5 mai 2025, 15:13 UTC

Market Talk

Résultats

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

15 nov. 2024, 11:14 UTC

Market Talk

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15 nov. 2024, 10:34 UTC

Market Talk

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

Comparaison

Variation de prix

BioNTech SE ADR prévision

Objectif de Prix

By TipRanks

23.99% hausse

Prévisions sur 12 Mois

Moyen 139.44 USD 23.99%

Haut 185 USD

Bas 112 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

17 ratings

Achat

Maintien

Vente

Basé sur 17 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

92.4 / 103.5Support & Résistance

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

173 / 371Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac